Tadalafil Tablet
Product Images NDC 72789-184

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-184). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789184 Label (72789184)

Label for Tadalafil USP 10 mg tablets by PD-Rx Pharmaceuticals, Inc., containing 90 tablets. The label includes the NDC 72789-184-90, lot number H21C09, expiration date 08/2023, and reorder numbers 111198 and 111198. It warns to keep out of reach of children and directs to see package insert for dosage and storage. Instructions for tablet dosage are provided in English and Spanish.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period. Two series are compared: Tadalafil 5 mg and placebo, with Tadalafil showing a greater reduction in score over time. The x-axis represents treatment duration in weeks, and the y-axis represents the change in IPSS score.*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs displaying blood pressure changes over time after Tadalafil administration in relation to placebo. The graphs show differences in standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, plotted against time in hours up to 96 hours.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs depicting the changes in systolic blood pressure (BP) over 24 hours post-dose. The top graph shows standing systolic BP and the bottom shows supine systolic BP. The graphs compare the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg over time.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph showing the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. Four groups are compared based on tadalafil dosing (08:00 or 20:00) and presence of placebo or tadalafil, all with 8 mg doxazosin at 08:00.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) over time (hours) for three different dosing regimens: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. Data points include error bars illustrating variation.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment period. It compares two groups: Tadalafil 5 mg and placebo, showing a greater decrease in score for Tadalafil. The x-axis represents duration of treatment in weeks, and the y-axis shows change in score values.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS total score, indicating symptom improvement over time for both groups, with more pronounced improvement in the Tadalafil 5 mg group.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph depicting the least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride versus Placebo/Finasteride. The graph shows data points at 0, 4, 12, and 26 weeks with statistical significance markers (p-values) indicated.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil depicted with labeled atoms and bonds, showing its distinct fused ring system and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.